錦欣生殖(01951.HK)擬收購武漢黃浦醫院75%股權
格隆匯 6 月 29日丨錦欣生殖(01951.HK)宣佈,於2020年6月29日,公司的間接全資附屬公司四川錦欣與武漢黃浦中西醫結合婦產醫院有限責任公司("武漢黃浦醫院")的若干股東("賣方")訂立股權轉讓協議,據此,四川錦欣將收購武漢黃浦醫院的合共75%股權(其中70%股權將由四川錦欣持有,5%股權未來將由四川錦欣指定的獨立法定主體持有以用於員工激勵目的)。於收購事項完成後,武漢黃浦醫院將成為集團的非全資附屬公司。
據悉,武漢黃浦醫院為一家位於中國湖北省武漢市江岸區的營利性三級專業婦產醫院,其為武漢擁有體外受精("IVF")牌照以向患者提供輔助生殖服務("ARS")(包括常規體外受精及胚胎移植("IVF-ET")以及卵胞漿內單精子注射("ICSI"))僅有的兩所非公立及營利性醫院之一。
公告稱,收購事項符合集團確立的戰略,即憑藉其於中國的領先地位,通過專注於收購已具備常規IVF-ET及ICSI牌照且位於具有巨大市場潛力的地理位置的目標ARS供應商來拓展平台。湖北省有約5,927萬人,然而,湖北省的ARS市場相對分散,沒有任何絕對主導的ARS供應商。憑藉在四川省及廣東省的成功經驗,集團旨在成為湖北省領先的ARS供應商。此外,收購事項使集團能夠戰略性地將其業務拓展到人口眾多及人均收入高的新地區。集團計劃利用其品牌,整合現有資源及吸引區域市場的頂尖人才及關鍵意見領袖,以建立強大的醫療團隊及滿足未滿足的醫療需求。此外,收購事項將進一步提高集團於中國ARS網絡的市場份額、生產力及產能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.